Across TCGA pan-cancer cohorts, IGLV4-3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLV4-3 data layer compared with 17 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGLV4-3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV4-3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where IGLV4-3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.272	0.702	.004	34	view →
PDAC	DFS	Quartile	All	0.658	1.000	.040	4	view →
CCRCC	DFS	Median	All	0.863	0.580	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV4-3 tumor-vs-normal RNA expression · all IGLV4-3 data types